// App-Quantinova.ai

5031 : Very Low to Low Doses of Continuous Azacitidine in Combination with Standard Doses of Lenalidomide and Low-Dose Dexamethasone (Rd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Interim Results of a Phase I/II Study

Researchers

Presenter

  • Shahper N Khan

Principal Investigators

  • Reda Z Mahfouz

  • Tamila L. Kindwall-Keller

  • Jason Valent

  • Christy Samaras

  • Ronald Sobecks

  • Carolyn Jirousek

  • Hien K. Duong

  • Mohammed Orloff

  • Yogen Saunthararajah

  • Robert M Dean

  • Beth Faiman

  • Janice Reed

  • Mary Ann Karam

  • Kimberly Hamilton

  • Sherry Fada

  • Matt Kalaycio

  • Erica L. Campagnaro

Medical Centers

  • Department of Internal Medicine, University of Virginia Medicial Center, Charlottesville, VA, USA,

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Deep vein thrombosis

  • Primary plasma cell leukemia

  • Venous thrombosis

  • Multiple Myeloma

  • Thrombocytopenia

  • Neutropenia

  • Depression

Biomarkers

  • Cluster of Differentiation 34

  • Cytidine deaminase

  • Syndecan-1

  • ZFP36 Ring Finger Protein Like 1

  • DNA methylation

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Vidaza

  • carfilzomib Intravenous

  • Bortezomib

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved